Fig. 3From: Comparison of the outcomes between sorafenib and lenvatinib as the first-line systemic treatment for HBV-associated hepatocellular carcinoma: a propensity score matching analysisProgression free survival. Kaplan–Meier estimates of progression free survival by treatment group. PFS, progression free survival; HR, hazard ratio; CI, confidence intervalBack to article page